We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
+19.6%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$269M
AUM Growth
+$71.2M
Cap. Flow
+$40.1M
Cap. Flow %
14.87%
Top 10 Hldgs %
31.44%
Holding
57
New
13
Increased
18
Reduced
17
Closed
7

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$7.45M
2
BIIB icon
Biogen
BIIB
+$5.55M
3
AMGN icon
Amgen
AMGN
+$5.51M
4
CNC icon
Centene
CNC
+$5.15M
5
ZBH icon
Zimmer Biomet
ZBH
+$4.98M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$5.18M
2
BDX icon
Becton Dickinson
BDX
+$5.06M
3
CELG
Celgene Corp
CELG
+$4.96M
4
ALC icon
Alcon
ALC
+$3.15M
5
DGX icon
Quest Diagnostics
DGX
+$2.35M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
1
Humana
HUM
$43.5B
$10.1M 3.74%
27,500
-1,500
-5% -$476K
HCA icon
2
HCA Healthcare
HCA
$86.8B
$9.24M 3.43%
62,500
+2,500
+4% +$336K
CNC icon
3
Centene
CNC
$31.7B
$8.49M 3.15%
135,000
+95,000
+238% +$5.15M
BMY icon
4
Bristol-Myers Squibb
BMY
$135B
$8.35M 3.1%
+130,000
New +$7.45M
ELV icon
5
Elevance Health
ELV
$82B
$8.31M 3.08%
27,500
+12,500
+83% +$3.44M
CI icon
6
Cigna
CI
$72.4B
$8.18M 3.04%
40,000
+20,000
+100% +$3.67M
THC icon
7
Tenet Healthcare
THC
$20.4B
$8.18M 3.03%
215,000
+40,000
+23% +$1.2M
UNH icon
8
UnitedHealth
UNH
$370B
$8.08M 3%
27,500
+2,500
+10% +$654K
BSX icon
9
Boston Scientific
BSX
$71.1B
$7.91M 2.94%
175,000
-25,000
-13% -$1.05M
UHS icon
10
Universal Health Services
UHS
$10.2B
$7.89M 2.93%
55,000
+5,000
+10% +$713K
DHR icon
11
Danaher
DHR
$137B
$7.67M 2.85%
56,400
+5,640
+11% +$713K
SNY icon
12
Sanofi
SNY
$102B
$7.53M 2.8%
150,000
+10,000
+7% +$468K
REGN icon
13
Regeneron Pharmaceuticals
REGN
$78.3B
$7.51M 2.79%
20,000
– –
ISRG icon
14
Intuitive Surgical
ISRG
$130B
$7.39M 2.74%
37,500
+19,146
+104% +$3.58M
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$121B
$7.12M 2.64%
32,500
-7,500
-19% -$1.52M
MRK icon
16
Merck
MRK
$316B
$6.82M 2.53%
78,600
-10,480
-12% -$861K
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.7B
$6.76M 2.51%
80,000
+35,000
+78% +$2.64M
LLY icon
18
Eli Lilly
LLY
$995B
$6.57M 2.44%
50,000
-5,000
-9% -$580K
GRFS
19
Grifois
GRFS
$5.49B
$6.41M 2.38%
275,000
-20,000
-7% -$436K
AZN icon
20
AstraZeneca
AZN
$241B
$6.23M 2.31%
62,500
+22,500
+56% +$2.12M
AMGN icon
21
Amgen
AMGN
$210B
$6.03M 2.24%
+25,000
New +$5.51M
BIIB icon
22
Biogen
BIIB
$30.8B
$5.93M 2.2%
+20,000
New +$5.55M
BAX icon
23
Baxter International
BAX
$14.7B
$5.85M 2.17%
70,000
-5,000
-7% -$414K
TMO icon
24
Thermo Fisher Scientific
TMO
$209B
$5.68M 2.11%
17,500
+2,500
+17% +$758K
BIO icon
25
Bio-Rad Laboratories Class A
BIO
$8.91B
$5.55M 2.06%
15,000
-3,000
-17% -$1.06M
1
2 3

Similar funds

RSF
Rik Saylor Financial Fairfield, Ohio $132M AUM 16.04% 1-Year Est. Return
VF
Visa Foundation San Francisco, California $132M AUM 14.62% 1-Year Est. Return
AFP
ATX Financial Planning Austin, Texas $132M AUM
GCM
Graver Capital Management Columbus, Ohio $132M AUM 16.79% 1-Year Est. Return
TCPW
Twin City Private Wealth Winston-Salem, North Carolina $132M AUM 11.31% 1-Year Est. Return
GCM
Gunpowder Capital Management Towson, Maryland $132M AUM
PF
PlanVest Financial Gaithersburg, Maryland $131M AUM
DQRIM
Dale Q Rice Investment Management Vancouver, Washington $132M AUM 45.8% 1-Year Est. Return

Sivik Global Healthcare's Q4 2019 Portfolio in Review

As of Q4 2019, Sivik Global Healthcare held 57 positions worth $269M, up 36% from $198M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Sivik Global Healthcare deployed $40.1M of net new capital in Q4 2019, opening 13 new positions and adding to 18 existing holdings. Its largest new stake was Bristol-Myers Squibb: 130,000 shares worth $8.35M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Alcon, an estimated $3.15M trimmed.

  • Sivik Global Healthcare's largest Q4 2019 buy was Bristol-Myers Squibb: 130,000 shares worth $8.35M.
  • Sivik Global Healthcare added most to Centene in Q4 2019, an estimated $5.15M increase.
  • Sivik Global Healthcare's biggest Q4 2019 reduction was Alcon, cutting an estimated $3.15M.
  • Sivik Global Healthcare fully exited Wellcare Health Plans, Inc. in Q4 2019, selling an estimated $5.18M.
  • Sivik Global Healthcare's ten largest holdings make up 31% of its $269M portfolio in Q4 2019.
  • Sivik Global Healthcare opened 13 new positions and closed 7 in Q4 2019.
  • Sivik Global Healthcare's portfolio value rose 36% quarter-over-quarter to $269M.

Based on Sivik Global Healthcare's 13F filing for Q4 2019, filed 13 Feb 2020.